Advances in the medical treatment of pulmonary hypertension

Kidney & Blood Pressure Research
Michael DandelR Hetzer

Abstract

Increased pulmonary precapillary vascular resistance due to vasoconstriction and vasoproliferative processes is the basic pathophysiological mechanism in the development of pulmonary hypertension (PH). With the exception of pulmonary venous hypertension, where the primary cause of PH is left ventricular failure or mitral valvular disease, all the other PH categories will benefit to a greater or lesser extent from pulmonary vasodilator and antivasoproliferative therapy. Today, for this purpose, in addition to intravenous prostacyclin (epoprostenol), which is restricted to severe pulmonary arterial hypertension (NYHA class IV and late class III), other therapeutic options such as treatment with more stable prostacyclin analogs (oral beraprost, aerosolized iloprost), endothelin-receptor antagonists (bosentan) or phosphodiesterase inhibitors (sildenafil) are also available and these are especially useful for the treatment of the early stages of the disease. The recent progress in medical therapy has markedly increased the life expectancy in patients with pulmonary arterial hypertension and substantially improved their quality of life. Chronic hemodialysis (HD) patients show higher endothelin-1 (ET-1) activity in comparison to healt...Continue Reading

References

Jul 9, 1992·The New England Journal of Medicine·B W ChristmanJ E Loyd
Feb 1, 1991·Arthritis and Rheumatism·K YamaneT Masaki
Jun 29, 1990·Biochemical and Biophysical Research Communications·H RakugiN Suzuki
Dec 30, 1993·The New England Journal of Medicine·S Moncada, A Higgs
Jun 17, 1993·The New England Journal of Medicine·A GiaidD J Stewart
Feb 1, 1996·The New England Journal of Medicine·R J BarstUNKNOWN Primary Pulmonary Hypertension Study Group
May 1, 1996·Annals of Internal Medicine·H OlschewskiW Seeger
Nov 1, 1996·British Journal of Pharmacology·K M McCullochM R MacLean
Jun 1, 1997·Critical Care Medicine·M E CunninghamM A McMillen
Aug 1, 1997·Journal of the American College of Cardiology·S M ShapiroB H Brundage
Aug 1, 1997·American Journal of Respiratory and Critical Care Medicine·S H ParkR P Michel
Jan 27, 1999·Pulmonary Pharmacology & Therapeutics·M R MacLean
Jun 3, 1999·American Journal of Respiratory and Critical Care Medicine·R M TuderN F Voelkel
Aug 3, 1999·American Journal of Respiratory and Critical Care Medicine·H OlschewskiW Seeger
Aug 26, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M J KrowkaR H Wiesner
Oct 3, 1999·Physiological Reviews·S NarumiyaF Ushikubi
Oct 16, 1999·Journal of the American College of Cardiology·S Rich, V V McLaughlin
Oct 16, 1999·Journal of the American College of Cardiology·N NagayaT Kunieda

❮ Previous
Next ❯

Citations

Apr 25, 2009·Reproductive Biology and Endocrinology : RB&E·Chrisen H MaharajJohn G Laffey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.